Progress in Medicinal Chemistry, Volume 45

1st Edition

Editors: F.D. King G. Lawton
Hardcover ISBN: 9780444528087
eBook ISBN: 9780080471310
Imprint: Elsevier Science
Published Date: 19th February 2007
Page Count: 232
210.00 + applicable tax
130.00 + applicable tax
165.00 + applicable tax
187.00 + applicable tax
Unavailable
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


Table of Contents

Preface List of Contributors Hit and Lead Identification: Efficient practices for drug discovery DPPIV Inhibition: Promising Therapy for the Treatment of Type 2 Diabetes Recent Progress Towards Nonpeptide Ligands for the Melanocortin-4 Receptor Tuberculosis chemotherapy: recent developments and future perspectives Subject Index Author Index (Volumes 1-45) Subject Index (Volumes 1-45)

Description

The success of any drug discovery project relies upon the quality of the lead that initiates the lead optimization process. What defines a ‘quality lead’, where these ‘quality leads’ come from and how one discovers them has been the subject of intense debate within the pharmaceutical industry, relies upon defining those properties that historically have led to successful drug discovery. This volume addresses these questions and specifically discusses diabetes, obesity and tuberculosis.

Key Features

Presents the latest research in the field of drug discovery Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect

Readership

Chemists, biologists, doctors, pharmacists and anyone interested in the contemporary controversy about drugs, drug firms, and the community


Details

No. of pages:
232
Language:
English
Copyright:
© Elsevier Science 2007
Published:
Imprint:
Elsevier Science
eBook ISBN:
9780080471310
Hardcover ISBN:
9780444528087

Reviews

The success of any drug discovery project relies upon the quality of the lead that initiates the lead optimization process. What defines a ‘quality lead’, where these ‘quality leads’ come from and how one discovers them has been the subject of intense debate within the pharmaceutical industry, relies upon defining those properties that historically have led to successful drug discovery. This volume addresses these questions and specifically discusses diabetes, obesity and tuberculosis.


About the Editors

F.D. King Editor

Affiliations and Expertise

GlaxoSmithKline, Harlow, Essex, UK

G. Lawton Editor

Dr Geoff Lawton has extensive experience in new medicine discovery across many therapeutic areas in both large and small companies and is a co-inventor of a marketed drug (Cilazapril). He is a former Director of Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. He was for five years the research member of a global therapy area strategy planning team for inflammatory diseases, aligning research with the clinical development and marketing parts of the business. From 2003 to 2007 he was founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines. Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant for a number small and medium sized biotech companies, CROs, VCs, academic groups and medical research charities. Geoff serves on the Board of Antabio, a French biotech company developing tomorrow’s antibacterial drugs. He is a founder of INMedD, a new medicines discovery social enterprise.

Affiliations and Expertise

St. Ippolyts, Herts, UK